MOCS3-1 Antibody

What is the MOCS3 protein and what cellular functions does it perform?

MOCS3 (Molybdenum Cofactor Synthesis 3) plays a central role in the 2-thiolation of mcm(5)S(2)U at tRNA wobble positions of cytosolic tRNA(Lys), tRNA(Glu), and tRNA(Gln). It is essential during biosynthesis of the molybdenum cofactor, acting by mediating the C-terminal thiocarboxylation of sulfur carriers URM1 and MOCS2A. The N-terminus of MOCS3 first activates URM1 and MOCS2A as acyl-adenylates (-COAMP), then the persulfide sulfur on the catalytic cysteine is transferred to form thiocarboxylation (-COSH) of their C-terminus. This reaction likely involves hydrogen sulfide generated from the persulfide intermediate, which acts as a nucleophile towards URM1 and MOCS2A. Importantly, MOCS3 does not use thiosulfate as a sulfur donor; instead, NFS1 acts as a sulfur donor for thiocarboxylation reactions .

What types of MOCS3 antibodies are available for research applications?

MOCS3 antibodies are available in several formats with different host species and clonality characteristics:

Both polyclonal and monoclonal antibodies have distinct advantages depending on the experimental context. Polyclonal antibodies typically offer broader epitope recognition while monoclonal antibodies provide higher specificity to a single epitope .

What is the molecular weight of MOCS3 protein and how does this affect antibody detection?

The calculated molecular weight of MOCS3 protein is approximately 49,669 Da. When planning Western blotting experiments, researchers should expect to see bands at approximately 50 kDa, though post-translational modifications may cause slight variations in the observed molecular weight. When using antibodies targeting specific regions of MOCS3, it's important to note that some antibodies are raised against specific amino acid regions (e.g., aa 200 to C-terminus, aa 271-460, or aa 1-460) . This targeting specificity can affect which isoforms or fragments of MOCS3 will be detected in experimental samples.

What are the optimal applications for different MOCS3 antibodies?

Based on validated applications from multiple suppliers, MOCS3 antibodies demonstrate varying performance across experimental techniques:

For optimal results, researchers should perform their own validation at multiple dilutions to determine the best working concentration for their specific experimental conditions and sample types .

How should MOCS3 antibodies be stored and handled to maintain activity?

MOCS3 antibodies require specific storage conditions to maintain their activity and specificity. Most suppliers recommend storing the antibodies at -20°C for long-term storage (typically one year). For frequent use and short-term storage, 4°C is recommended for up to one month. The antibodies are generally provided in stabilizing buffers containing preservatives like sodium azide and glycerol. It is critical to avoid repeated freeze-thaw cycles as these can progressively degrade antibody performance. When working with these antibodies, allow them to equilibrate to room temperature before opening to prevent condensation, which can introduce contaminants and dilute the antibody solution .

What are the species reactivity profiles of available MOCS3 antibodies?

MOCS3 antibodies exhibit different cross-reactivity profiles that researchers should consider when selecting an appropriate antibody:

When working with non-human samples, researchers should select antibodies with validated cross-reactivity or perform their own validation. The higher degree of sequence homology between human MOCS3 and that of other mammals explains the cross-reactivity observed in some antibodies .

What are common causes of non-specific binding with MOCS3 antibodies and how can they be minimized?

Non-specific binding is a common challenge when working with MOCS3 antibodies. Several strategies can address this issue:

• Optimization of blocking: Use 5% non-fat milk or BSA in TBS-T for Western blots; test both to determine which gives cleaner results.

• Antibody dilution adjustment: Test a range of dilutions; sometimes higher dilutions reduce background while maintaining specific signal.

• Incubation conditions: For primary antibodies, overnight incubation at 4°C often improves specificity compared to shorter incubations at room temperature.

• Wash optimization: Increase wash volume, duration, or number of washes to reduce non-specific binding.

• Buffer optimization: Adding 0.1-0.5% Triton X-100 or NP-40 to wash buffers can help reduce hydrophobic interactions.

For monoclonal antibodies like the 1C5-E8 clone, non-specific binding is typically lower than with polyclonal antibodies, but optimization is still necessary for optimal results .

What controls should be included when validating MOCS3 antibodies for new applications?

Proper controls are essential for validating MOCS3 antibodies:

• Positive control: Samples known to express MOCS3 (e.g., specific human cell lines like HeLa or HEK293).

• Negative control: Samples with no or minimal MOCS3 expression, or MOCS3 knockdown/knockout samples.

• Primary antibody omission: Process samples without the primary antibody to assess secondary antibody non-specific binding.

• Isotype control: Use an irrelevant antibody of the same isotype and concentration to assess non-specific binding.

• Blocking peptide competition: Pre-incubate the antibody with the immunizing peptide to confirm specificity.

• Cross-validation: Compare results using multiple antibodies targeting different epitopes of MOCS3.

When establishing new applications, researchers should validate antibodies using multiple approaches to ensure reliable results .

How can signal intensity be improved in Western blots using MOCS3 antibodies?

To enhance signal intensity in Western blots using MOCS3 antibodies:

• Sample preparation: Ensure efficient extraction of MOCS3 protein by using appropriate lysis buffers with protease inhibitors.

• Protein loading: Optimize protein loading; MOCS3 may require higher loading amounts (50-80 μg) for detection in some samples.

• Transfer efficiency: Use PVDF membranes for stronger protein binding, and optimize transfer time and current.

• Blocking optimization: Test different blocking agents (milk vs. BSA) as some can interfere with antibody binding.

• Antibody concentration: Test higher concentrations of primary antibody (1:500 or 1:200 dilutions).

• Incubation time: Extend primary antibody incubation to overnight at 4°C.

• Detection system: Use more sensitive detection systems like enhanced chemiluminescence (ECL) or fluorescent secondary antibodies.

• Film exposure: For chemiluminescent detection, try multiple exposure times.

Different MOCS3 antibodies have varying optimal detection conditions, so researchers should consult specific product documentation and perform optimization for their experimental system .

How can MOCS3 antibodies be used to study protein-protein interactions involving MOCS3?

MOCS3 antibodies can be powerful tools for studying protein-protein interactions:

• Co-immunoprecipitation (Co-IP): MOCS3 antibodies can precipitate MOCS3 along with its binding partners. This is particularly useful for studying interactions with URM1, MOCS2A, and other components of the molybdenum cofactor synthesis pathway. When selecting antibodies for Co-IP, those validated for immunoprecipitation applications should be prioritized.

• Proximity Ligation Assay (PLA): This technique can visualize and quantify interactions between MOCS3 and potential binding partners in situ. It requires antibodies from different host species against each interacting protein.

• Pull-down assays: GST-tagged or His-tagged MOCS3 can be used alongside antibodies to identify novel interaction partners.

• Yeast two-hybrid verification: MOCS3 antibodies can verify interactions identified through yeast two-hybrid screens by confirming the presence of putative interacting proteins in co-immunoprecipitates.

When studying MOCS3 interactions, researchers should consider that the N-terminal adenylyltransferase domain and C-terminal rhodanese-like domain may have different interaction partners and might require domain-specific antibodies for comprehensive analysis .

What approaches can be used to evaluate antibody specificity in MOCS3 detection?

Comprehensive evaluation of MOCS3 antibody specificity requires multiple complementary approaches:

• Genetic validation: Testing samples with MOCS3 gene knockdown (siRNA/shRNA) or knockout (CRISPR-Cas9) to confirm the absence of signal. This approach represents the gold standard for specificity confirmation.

• Expression system validation: Overexpression of tagged MOCS3 in cell lines with subsequent detection using both tag-specific and MOCS3-specific antibodies to confirm concordant signals.

• Mass spectrometry verification: Immunoprecipitation followed by mass spectrometry analysis to confirm that the precipitated protein is indeed MOCS3.

• Multiple antibody comparison: Using different antibodies targeting distinct epitopes of MOCS3 to verify consistent detection patterns.

• Peptide competition: Pre-incubation of the antibody with the immunizing peptide should abolish specific signal in applications like Western blotting and immunohistochemistry.

• Cross-reactivity assessment: Testing against closely related proteins to ensure the antibody doesn't recognize unintended targets.

These approaches align with emerging standards for antibody validation in the research community and help ensure reliable experimental outcomes .

How can MOCS3 antibodies be applied in studies of tRNA modification and molybdenum cofactor synthesis?

MOCS3 antibodies enable detailed investigation of tRNA modification and molybdenum cofactor synthesis pathways:

• Subcellular localization: Immunofluorescence with MOCS3 antibodies can reveal the cellular compartments where MOCS3 functions, providing insights into the spatial organization of these pathways.

• Pathway dynamics: Combining MOCS3 immunodetection with stimuli that affect tRNA modification or molybdenum cofactor synthesis can reveal dynamic changes in MOCS3 localization, abundance, or post-translational modifications.

• Complex formation analysis: MOCS3 antibodies can help characterize the composition of protein complexes involved in these pathways through techniques like co-immunoprecipitation followed by Western blotting for specific partners.

• Developmental and tissue-specific expression: IHC with MOCS3 antibodies across tissues or developmental stages can reveal spatial and temporal regulation of these pathways.

• Disease models: MOCS3 antibodies can assess pathway dysregulation in models of diseases associated with defects in tRNA modification or molybdenum cofactor synthesis.

When designing such studies, researchers should consider that MOCS3 has dual functions in tRNA modification and molybdenum cofactor synthesis, so experimental design should carefully distinguish between these roles .

What criteria should guide selection between polyclonal and monoclonal MOCS3 antibodies?

Selection between polyclonal and monoclonal MOCS3 antibodies should be guided by specific experimental requirements:

For novel research where MOCS3 detection is being established, starting with polyclonal antibodies might provide better chances of detection. For standardized assays requiring reproducibility, monoclonal antibodies like the 1C5-E8 clone offer better consistency .

How do different MOCS3 antibody preparation methods affect experimental outcomes?

The preparation method of MOCS3 antibodies significantly impacts their performance characteristics:

• Recombinant fragment immunization: Antibodies generated against recombinant fragments of MOCS3 (e.g., aa 200 to C-terminus or full-length) may recognize different epitopes. Those targeting the N-terminal adenylyltransferase domain may be better for studying URM1/MOCS2A activation, while C-terminal rhodanese-domain antibodies might be preferable for studying sulfurtransferase activity.

• Peptide immunization: Antibodies raised against short peptides (e.g., aa 40-66) target very specific regions and may be less likely to detect MOCS3 if that region is masked by protein folding or interactions.

• Purification method: Affinity-purified antibodies typically show higher specificity than crude sera or protein A/G purified antibodies. Immunogen affinity chromatography, used for several commercial MOCS3 antibodies, provides the highest specificity.

• Conjugation status: While most MOCS3 antibodies are unconjugated, some are available with biotin or HRP conjugation, which affects detection strategy and sensitivity.

When selecting MOCS3 antibodies, researchers should match the antibody preparation method to their specific experimental needs, considering factors like the region of MOCS3 they wish to study and the detection method they plan to use .

What developmental factors should be considered when using MOCS3 antibodies in diverse experimental systems?

The developability of antibodies, including those targeting MOCS3, encompasses several factors that affect their utility across experimental systems:

• Expression levels: MOCS3 expression varies across tissues and cell types, requiring antibodies with appropriate sensitivity for each system. Preliminary studies suggest higher expression in metabolically active tissues, which should guide sample selection and loading volumes.

• Solubility and viscosity: Antibody formulation affects performance in different applications. High-concentration antibody solutions may exhibit increased viscosity or aggregation, particularly problematic for microinjection or microfluidic applications.

• Buffer compatibility: Different experimental systems may require specific buffer conditions that could affect antibody binding. Testing compatibility with common additives (detergents, reducing agents, etc.) is advisable.

• Binding kinetics: The association and dissociation rates of MOCS3 antibodies can vary, affecting their performance in techniques like surface plasmon resonance or bio-layer interferometry.

• Computational predictive approaches: As demonstrated in antibody development studies, in silico tools like CamSol can predict antibody developability characteristics, potentially reducing the need for extensive in vitro testing when selecting between multiple candidate antibodies.

Researchers should employ both computational predictions and focused in vitro testing to assess the suitability of MOCS3 antibodies for their specific experimental systems, particularly for novel or challenging applications .